Advanced NMR calls off AMS merger

Article

Advanced NMR announced last week that it has canceled its proposedmerger with Advanced Mammography Systems, the breast MRI developerof which it owns a majority interest.Advanced NMR, of Wilmington, MA, had originally planned to bringAMS under its wing

Advanced NMR announced last week that it has canceled its proposedmerger with Advanced Mammography Systems, the breast MRI developerof which it owns a majority interest.

Advanced NMR, of Wilmington, MA, had originally planned to bringAMS under its wing because of capitalization issues at the subsidiary.AMS recently completed a private placement of $3 million worthof convertible debentures, however, enabling the unit to remainindependent. Proceeds from the debenture issue will be used toaccelerate the completion of product development for AdvancedMammography Systems' Aurora dedicated breast MRI scanner and tofund a global product launch of the machine.

The merger cancellation renders moot a class action shareholderlawsuit filed against Advanced NMR earlier this year seeking tostop the merger (SCAN 2/28/96). Advanced NMR will continue toown 61% of AMS.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.